EC Number   |
Expression |
Reference |
|---|
   3.4.21.109 | down |
Epi/MTP is expressed at low level in the mouse mammary epithelium of young animals |
709803 |
| 3.4.21.109 | down |
immunoreactivity of matriptase, hepatcyte growth factor activator inhibitor-1 and proteinase-activated receptor 2 is shown to be diminished in basal cell carcinomas |
709407 |
| 3.4.21.109 | more |
in Hep-G2 cells stably expressing the coding sequence of gene TMPRSS6, encoding the enzyme, incubation with apo-transferrin or the membrane-impermeable iron chelator deferoxamine mesylate salt, increases enzyme levels. This increase does not result from the inhibition of enzyme shedding from the cells |
732181 |
| 3.4.21.109 | up |
level of Epi/MTP is elevated in the mammary glands at stages when epithelial proliferation and modeling occur |
709803 |
| 3.4.21.109 | up |
matriptase expression is increased with squamous cell carcinoma progression |
709407 |
| 3.4.21.109 | up |
matriptase gene expression is significantly elevated in patients with osteoarthritis cartilage compared with patients with fracture to the neck of the femur cartilage |
707324 |
| 3.4.21.109 | up |
matriptase zymogen is down-regulated in the UROtsa cells by ibuprofen |
753089 |
| 3.4.21.109 | up |
RT-PACR analysis reveal a 1000fold higher matriptase expression in human pancreatic adenocarcinoma AsPC-1 cells than in the MDA-MB-435S cells |
708768 |
| 3.4.21.109 | up |
the enzyme is up-regulated under iron deprivation |
732181 |
| 3.4.21.109 | up |
using immunohistochemistry a significant overexpression of matriptase is shown in pancreatic carcinoma compared to normal pancreatic ducts |
708791 |
